Literature DB >> 16307646

CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.

J Lang1, M Boxer, R M MacKie.   

Abstract

BACKGROUND: Up to 5% of patients with melanoma have a family history of a first-degree relative also being affected.
OBJECTIVES: To study such families for germline mutations, to help clarify the gene-environment interaction in melanoma aetiology.
METHODS: Thirty-two families in Scotland with melanoma in two or more first-degree relatives are reported for the first time. Peripheral blood DNA was extracted, and denaturing high-performance liquid chromatography analysis performed on exons 1alpha and 2 of the CDKN2A gene and their splice junctions. The coding sequences and splice junctions of these exons were sequenced in all samples as confirmation of the chromatographic pattern observed.
RESULTS: Seven of the 32 melanoma families (22%) have CDKN2A mutations. One mutation, H83N, which has not previously been described in melanoma families, was found in one family. In addition, two families have R112G mutations, one family has a G67R mutation, one has an exon 1alpha 24-bp duplication where bases 9-32 are duplicated between bases 32 and 33, and two families have M53I mutations, bringing the total of known Scottish families with the M53I mutation to six.
CONCLUSIONS: This study brings the total of Scottish families investigated for germline mutations to 48, and strongly suggests that the M53I mutation originated in Scotland.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307646     DOI: 10.1111/j.1365-2133.2005.06846.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

1.  A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds.

Authors:  Julie M Lang; Michael Shennan; Jenny C-N Njauw; Su Luo; Julia N Bishop; Mark Harland; Nicholas K Hayward; Margaret A Tucker; Alisa M Goldstein; Maria T Landi; Susana Puig; Nelleke A Gruis; Wilma Bergman; Giovanna Bianchi-Scarra; Paola Ghiorzo; David Hogg; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

2.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

3.  Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.

Authors:  F Demenais; H Mohamdi; V Chaudru; A M Goldstein; J A Newton Bishop; D T Bishop; P A Kanetsky; N K Hayward; E Gillanders; D E Elder; M F Avril; E Azizi; P van Belle; W Bergman; G Bianchi-Scarrà; B Bressac-de Paillerets; D Calista; C Carrera; J Hansson; M Harland; D Hogg; V Höiom; E A Holland; C Ingvar; M T Landi; J M Lang; R M Mackie; G J Mann; M E Ming; C J Njauw; H Olsson; J Palmer; L Pastorino; S Puig; J Randerson-Moor; M Stark; H Tsao; M A Tucker; P van der Velden; X R Yang; N Gruis
Journal:  J Natl Cancer Inst       Date:  2010-09-28       Impact factor: 13.506

Review 4.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

5.  Familial Melanoma: Diagnostic and Management Implications.

Authors:  Mariarita Rossi; Cristina Pellegrini; Ludovica Cardelli; Valeria Ciciarelli; Lucia Di Nardo; Maria Concetta Fargnoli
Journal:  Dermatol Pract Concept       Date:  2019-01-31

6.  A common variant of the p16(INK4a) genetic region is associated with physical function in older people.

Authors:  David Melzer; Timothy M Frayling; Anna Murray; Alison J Hurst; Lorna W Harries; Honglin Song; Kaytee Khaw; Robert Luben; Paul G Surtees; Stefania S Bandinelli; Anna-Maria Corsi; Luigi Ferrucci; Jack M Guralnik; Robert B Wallace; Andrew T Hattersley; Paul D Pharoah
Journal:  Mech Ageing Dev       Date:  2007-03-27       Impact factor: 5.432

7.  Survival from melanoma of the skin in England and Wales up to 2001.

Authors:  C H Ottensmeier; M Gore
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

8.  Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.

Authors:  Joan Anton Puig-Butille; María José Escámez; Francisco Garcia-Garcia; Gemma Tell-Marti; Àngels Fabra; Lucía Martínez-Santamaría; Celia Badenas; Paula Aguilera; Marta Pevida; Joaquín Dopazo; Marcela del Río; Susana Puig
Journal:  Oncotarget       Date:  2014-03-30

Review 9.  Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention.

Authors:  Michele Manganelli; Stefania Guida; Anna Ferretta; Giovanni Pellacani; Letizia Porcelli; Amalia Azzariti; Gabriella Guida
Journal:  Genes (Basel)       Date:  2021-07-19       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.